ID | 1183 |
Name of the vaccine | Pentastaph |
Microbe | Bacteria |
Disease name | Methicillin-Resistant Staphylococcus aureus (MRSA) |
Name of bacteria | Staphylococcus aureus |
Type of vaccine | Conjugate |
Nucleic acid content | Circular DNA |
Age | NA |
Description of the vaccine | Pentavalent S. aureus vaccine. |
Name of the manufacturer | NABI/GSK |
Name of the manufacturing country | NA |
Year of manufacture | 2009 |
Clinical Phase status | Clinical - Failed |
Bacterial strain | Gram-positive bacteria. |
Efficacy | NA |
Vaccine formulation | NA |
Dosage | NA |
Mechanism of action | Induces antibodies that target S. aureus capsular polysaccharides types 5, 8 and the cell wall antigen type 336. |
Route of administration | NA |
Indications | Prevention and treatment of S. aureus infections. |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | NA |
Interspecies transfer | NA |
PubMed identifier | 21501445 |
Clinical trial number | NA |
Reference | https://www.who.int/immunization/research/forums_and_initiatives/4_OSchneewind_Staphylococcal_Vaccines_gvirf16.pdf?ua=1 |
Other name | NA |
Additional Links | https://www.fiercebiotech.com/biotech/nabi-biopharmaceuticals-and-niaid-to-advance-pentastaph-vaccine-research
|